首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1383658

鼻疫苗市场，2028-全球产业规模、份额、趋势、机会和预测，2018-2028 按疫苗类型、按应用（流感、COVID-19、其他）、按地区、按竞争细分。

Nasal Vaccines Market, 2028- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type, By Application (Influenza, COVID-19, Others ), By Region, By Competition.

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022 年，全球鼻腔疫苗市场价值为 3.7523 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2028 年CAGR为6.11%。全球医疗保健格局在不断发展，近年来的一项重大发展是鼻疫苗的出现鼻疫苗。鼻疫苗提供了一种新颖有效的方法来预防各种传染病，为传统注射疫苗提供了一种非侵入性替代方案。随着疫苗技术的进步和对其益处的认识不断提高，全球鼻疫苗市场一直在增长势头。近年来，在几个关键因素的推动下，全球鼻疫苗市场出现了大幅成长。其中包括对无痛便捷疫苗接种方法的需求不断增长、对预防性医疗保健的日益关注以及创新鼻疫苗配方的开发。鼻疫苗对于害怕针头的儿童和个人特别有吸引力，使其成为免疫接种的首选。

市场上经鼻给药的疫苗类型不断扩大。最初，鼻腔疫苗主要与流感疫苗有关，但现在它们涵盖更广泛的疾病，包括 COVID-19、麻疹、腮腺炎、德国麻疹等。这种多元化极大地提振了市场。製药公司和研究机构正在积极投资研发，以开发更有效、更有效的鼻疫苗配方。这包括增强鼻疫苗的稳定性和传递机制。

各国政府和国际组织越来越认识到鼻疫苗在提高疫苗接种覆盖率方面的潜力。这导致对使用鼻疫苗的研究和疫苗接种活动的投资增加，特别是在低收入和中等收入国家。公众意识活动和教育工作在提高鼻疫苗的接受度方面发挥着至关重要的作用。这些活动强调了鼻疫苗的优点，例如减轻疼痛、更容易给药和更快的免疫力发展。

市场概况
预测期	2024-2028
2022 年市场规模	37523万美元
2028 年市场规模	5.3347亿美元
2023-2028 年CAGR	6.11%
成长最快的细分市场	减毒活疫苗
最大的市场	北美洲

肯塔基州市场驱动因素

市场规模及预测
- 按价值
市占率及预测
- 依疫苗类型（减毒活疫苗、不活化疫苗、次单位疫苗、重组疫苗及结合疫苗等）
- 按应用（流感、COVID-19、其他（如霍乱、伤寒等））
- 按地区
- 按公司划分（前 5 名市场参与者的股份）
市场地图
- 按疫苗类型
- 按应用
- 按地区

第 6 章：北美鼻腔疫苗市场展望

市场规模及预测
- 按价值
市占率及预测
- 按疫苗类型
- 按应用
- 按国家/地区

第 7 章：欧洲鼻腔疫苗市场展望

市场规模及预测
- 按价值
市占率及预测
- 按疫苗类型
- 按应用
- 按最终用户
- 按国家/地区

第 8 章：亚太地区鼻腔疫苗市场展望

市场规模及预测
- 按价值
市占率及预测
- 按疫苗类型
- 按应用
- 按国家/地区

第 9 章：南美洲鼻腔疫苗市场展望

市场规模及预测
- 按价值
市占率及预测
- 按疫苗类型
- 按应用
- 按国家/地区

第 10 章：中东和非洲鼻疫苗市场展望

市场规模及预测
- 按价值
市占率及预测
- 按疫苗类型
- 按应用
- 按国家/地区

第 11 章：市场动态

司机
挑战

第 12 章：市场趋势与发展

近期发展
併购
技术发布

第13章：竞争格局

BiondVax 製药有限公司
- Business Overview
- Application Offerings
- Recent Developments
- Key Personnel
- SWOT Analysis
瓦克斯特公司
氟基因公司
阿尔提免疫公司
科兴生物科技有限公司
赛诺菲巴斯德公司
辉瑞公司
葛兰素史克公司
强生公司
Ennaid 治疗有限责任公司

第 14 章：策略建议

关于我们及免责声明

简介目录

Product Code: 17572

Global Nasal Vaccines Market has valued at USD 375.23 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.11% through 2028. The global healthcare landscape is continually evolving, and one significant development in recent years is the emergence of nasal vaccines. Nasal vaccines offer a novel and effective way to protect against various infectious diseases, providing a non-invasive alternative to traditional injection-based vaccines. The global nasal vaccines market has been gaining momentum, with advancements in vaccine technology and increasing awareness of their benefits. The global nasal vaccines market has witnessed substantial growth in recent years, driven by several key factors. These include a rising demand for painless and convenient vaccination methods, increased focus on preventive healthcare, and the development of innovative nasal vaccine formulations. Nasal vaccines are particularly appealing for children and individuals who fear needles, making them a preferred choice for immunization.

The market has seen the expansion of the types of vaccines delivered nasally. Initially, nasal vaccines were primarily associated with influenza vaccines, but now they cover a wider range of diseases, including COVID-19, measles, mumps, rubella, and more. This diversification has significantly boosted the market. Pharmaceutical companies and research institutions are actively investing in R&D to develop more effective and potent nasal vaccine formulations. This includes enhancing the stability and delivery mechanisms of nasal vaccines.

Governments and international organizations are increasingly recognizing the potential of nasal vaccines in improving vaccination coverage rates. This has led to greater investments in research and vaccination campaigns using nasal vaccines, particularly in low-income and middle-income countries. Public awareness campaigns and educational efforts are playing a vital role in increasing the acceptance of nasal vaccines. These campaigns highlight the advantages of nasal vaccines, such as reduced pain, easier administration, and quicker immunity development.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 375.23 Million
Market Size 2028	USD 533.47 Million
CAGR 2023-2028	6.11%
Fastest Growing Segment	Live Attenuated Vaccines
Largest Market	North America

Ky Market Drivers

Rising Infectious Disease Threats is Driving the Global Nasal Vaccines Market

Infectious diseases have been a perennial threat to human health throughout history. From the bubonic plague to influenza pandemics, these diseases have shaped societies, economies, and public health strategies. In recent years, the world has witnessed the emergence of new infectious diseases and the resurgence of existing ones, driving a heightened focus on prevention and vaccination. One promising avenue in the fight against infectious diseases is nasal vaccines, which have gained momentum due to their effectiveness, ease of administration, and potential for broader coverage.

Infectious diseases have historically posed significant challenges to public health. The emergence of highly contagious diseases, such as COVID-19, Zika, and Ebola, has highlighted the need for innovative vaccination strategies. Traditional vaccines, which are typically administered via injection, have been effective in controlling many infectious diseases. However, they often face logistical hurdles, such as cold chain requirements, and can be less accessible in resource-constrained settings. Nasal vaccines offer a novel solution to these challenges. Administered through the nasal mucosa, these vaccines provide several advantages over traditional injectable vaccines. The nasal route is a natural portal of entry for many respiratory and enteric pathogens, making it an ideal site for vaccination. Additionally, nasal vaccines are needle-free, reducing the fear and discomfort associated with injections. They can also stimulate mucosal immune responses, which are crucial for defending against respiratory and gastrointestinal infections.

The global pharmaceutical industry has recognized the potential of nasal vaccines and is actively investing in research and development in this field. As a result, the nasal vaccines market is witnessing rapid growth and diversification. Several companies and research institutions are working on nasal vaccine candidates for a wide range of infectious diseases. Nasal vaccines for influenza have been a major focus, given the virus's seasonal nature and potential for pandemics. These vaccines offer an attractive alternative to traditional flu shots, particularly for young children and individuals with needle phobias. The COVID-19 pandemic accelerated research into nasal vaccines. Intranasal COVID-19 vaccines have been developed to provide local immunity in the respiratory tract, potentially reducing transmission and enhancing protection against variants. Nasal vaccines for Respiratory Syncytial Virus (RSV) are being explored, as this virus poses a significant risk to infants and older adults. RSV is responsible for a substantial burden of hospitalizations each year, making the development of an effective nasal vaccine a high priority.

Nasal vaccines for rotavirus, a common cause of severe diarrhea in young children, are being investigated. These vaccines could have a significant impact on reducing childhood mortality in low-resource settings. The growing portfolio of nasal vaccines is expanding the global market for these innovative vaccines. Increased investments in research and development are driving innovation, resulting in safer and more effective products. Moreover, partnerships between pharmaceutical companies and global health organizations are promoting equitable access to these vaccines in low- and middle-income countries. Furthermore, the ease of administration of nasal vaccines can help improve vaccination rates, especially among children and individuals with needle aversions. This accessibility could have a profound impact on public health by increasing vaccine coverage and reducing the spread of infectious diseases.

Expanding Geriatric Population is Driving the Global Nasal Vaccines Market

The global healthcare landscape is undergoing a significant transformation as the world's population continues to age rapidly. One of the most profound consequences of this demographic shift is the increased susceptibility of older individuals to various infectious diseases. As a result, there has been a growing emphasis on developing innovative vaccination strategies to protect this vulnerable population. Nasal vaccines have emerged as a promising solution, and their demand is being propelled by the expanding geriatric population. The world is witnessing an unprecedented increase in the number of elderly individuals. This demographic shift is primarily attributed to declining birth rates and improved healthcare, which have led to longer life expectancies. According to the World Health Organization (WHO), the global population aged 60 and older is expected to reach 2.1 billion by 2050, nearly doubling from 962 million in 2017. This demographic change presents a unique set of healthcare challenges, one of which is the heightened vulnerability of the elderly to infectious diseases. Aging is associated with a natural decline in the immune system's function, a phenomenon known as immunosenescence. This decline makes older individuals more susceptible to infections, including respiratory diseases like influenza, pneumonia, and COVID-19. Moreover, aging is often accompanied by the presence of chronic medical conditions, further increasing the risk of severe complications from infectious diseases.

Traditional vaccines, which are typically administered through injections, may be less effective in older individuals due to the weakened immune response associated with aging. This limitation has led researchers to explore alternative vaccination methods that can stimulate a robust immune response in the elderly. Nasal vaccines, which are administered intranasally, have gained significant attention for their potential to address these challenges.

Nasal vaccines can overcome the age-related decline in immune function by directly targeting the respiratory mucosa, where many respiratory pathogens enter the body. Many older individuals may have difficulty with injections due to age-related frailty or fear of needles. Nasal vaccines eliminate the need for injections, making them more accessible and acceptable to the elderly. Nasal vaccines are non-invasive and easy to administer, making them suitable for older adults with mobility issues or cognitive impairments. Nasal vaccines can be administered as booster doses to enhance immunity over time, which is especially important for the geriatric population to maintain protection against evolving pathogens.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the nasal vaccines market is navigating the complex regulatory landscape. The approval process for nasal vaccines can be more challenging compared to traditional injectable vaccines. Regulators need to ensure the safety and efficacy of these vaccines, which can lead to longer development timelines and higher costs. To address this challenge, collaboration between vaccine developers and regulatory agencies is essential to streamline the approval process and establish clear guidelines for nasal vaccine development.

Vaccine Stability and Shelf Life

Nasal vaccines can be sensitive to environmental factors, including temperature and humidity, which can affect their stability and shelf life. Maintaining the integrity of nasal vaccine formulations during storage and transportation is critical to their success. Innovations in vaccine formulation and packaging technologies are necessary to improve stability and extend shelf life, ensuring that vaccines remain effective from production to administration.

Efficacy and Immunogenicity

Achieving high levels of efficacy and immunogenicity is a paramount concern for nasal vaccines. The nasal mucosa is a unique immune environment, and developing vaccines that elicit strong and lasting immune responses can be challenging. Researchers are actively working on enhancing the immunogenicity of nasal vaccines through novel adjuvants, delivery systems, and antigen design. Additionally, clinical trials should be designed carefully to assess the effectiveness of nasal vaccines and compare them to established injectable counterparts.

Manufacturing Capacity

Scaling up the production of nasal vaccines to meet global demand can be a formidable challenge. The manufacturing processes for nasal vaccines differ from traditional vaccine production, requiring specialized equipment and expertise. Building and expanding manufacturing facilities and ensuring a consistent supply chain are essential to meet the growing demand for nasal vaccines. Collaborations with contract manufacturers and technology transfer agreements may also be necessary to increase production capacity.

Public Awareness and Acceptance

Public perception and acceptance of nasal vaccines play a significant role in their adoption. Some individuals may be skeptical or unfamiliar with this mode of vaccination, leading to hesitancy or reluctance to receive nasal vaccines. Raising public awareness about the safety, efficacy, and convenience of nasal vaccines through education and targeted communication campaigns is crucial for their widespread acceptance.

Competition from Injectable Vaccines

Injectable vaccines have been the standard for decades, and they have a well-established track record of success. Nasal vaccines face competition from these tried-and-true alternatives, which can hinder their market penetration. To overcome this challenge, nasal vaccine developers must demonstrate clear advantages over injectable vaccines, such as improved efficacy, ease of administration, or reduced side effects.

Key Market Trends

Technological Advancements

The global healthcare landscape is constantly evolving, with technological advancements at the forefront of innovation. One significant development is the growing interest in nasal vaccines, a novel approach to immunization that offers numerous advantages over traditional injection-based vaccines. These advancements have ignited a surge in the Global Nasal Vaccines Market, shaping the future of preventive medicine and public health.

Advancements in vaccine formulation have played a pivotal role in the growth of nasal vaccines. Researchers are developing new formulations that enhance vaccine stability, improve antigen delivery, and minimize side effects, thereby increasing their efficacy and safety. Adjuvants are substances added to vaccines to boost the body's immune response. Recent developments in adjuvant technology have led to the creation of nasal vaccines that can trigger stronger and more durable immune responses, improving their overall effectiveness.

Nanotechnology has revolutionized vaccine delivery. Nanoparticles can be used to encapsulate vaccine antigens, allowing for controlled release and targeted delivery. This technology enables the development of nasal vaccines with improved immunogenicity.

Advances in reverse genetics have facilitated the development of genetically engineered vaccines. This technology enables the precise manipulation of viral genes, resulting in safer and more effective vaccines. Nasal vaccines based on reverse genetics have shown promise in combating influenza and other respiratory viruses. Nasal vaccines are often more stable at higher temperatures, reducing the need for cold chain storage and transportation. This eliminates the logistical challenges associated with maintaining the cold chain, especially in remote or underserved areas.

Segmental Insights

Vaccine Type Insights

Based on the category of Vaccine Type, the Live Attenuated Vaccines emerged as the dominant player in the global market for Nasal Vaccines in 2022. Live attenuated vaccines are developed by weakening a disease-causing pathogen, such as a virus or bacterium, to the point where it can no longer cause disease in healthy individuals. However, the attenuated pathogen is still capable of stimulating a robust immune response. When administered nasally, live attenuated vaccines can closely mimic natural infection, providing a more comprehensive and durable immune response. The nasal mucosa is rich in immune cells, making it an ideal site for vaccine administration. Live attenuated vaccines delivered through the nasal route can induce a strong and local immune response, including the production of secretory IgA antibodies, which play a crucial role in mucosal defense. Live attenuated influenza vaccines (LAIV), such as FluMist, have been developed to protect against seasonal flu. Administered as a nasal spray, LAIV has gained popularity, especially among children, due to its ease of administration.

Application Insights

The Influenza segment is projected to experience rapid growth during the forecast period. Rats are versatile research animals Influenza, commonly known as the flu, is a highly contagious respiratory infection caused by influenza viruses. It has been a perennial health concern for people worldwide, leading to a significant economic and healthcare burden. To combat this contagious menace, the global healthcare industry has been continually striving to enhance prevention methods, and one promising avenue gaining traction is the use of nasal vaccines. In recent years, influenza has emerged as a dominant force in the global nasal vaccines market, promising a more effective and convenient approach to influenza prevention.

Regional Insights

North America emerged as the dominant player in the global Nasal Vaccines market in 2022, holding the largest market share in terms of value. North America boasts some of the world's leading pharmaceutical and biotech companies, as well as world-renowned research institutions. These organizations are at the forefront of nasal vaccine development, investing heavily in research and development to create effective and safe nasal vaccines for a range of infectious diseases The regulatory environment in North America is conducive to innovation and development. Regulatory agencies like the Food and Drug Administration (FDA) in the United States have been supportive of nasal vaccine research, expediting approvals for promising candidates. This encourages companies to invest in the development of new nasal vaccines.

Key Market Players

Vaxart, Inc.

FluGen Inc.

Altimmune, Inc.

Sinovac Biotech Ltd.

Sanofi Pasteur SA

Pfizer Inc.

GlaxoSmithKline plc

Johnson & Johnson

Ennaid Therapeutics, LLC

Report Scope:

In this report, the Global Nasal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nasal Vaccines Market, By Vaccine Type:

Live Attenuated Vaccines
Inactivated Vaccines
Subunit Recombinant and Conjugate Vaccines
Others

Nasal Vaccines Market, By Application:

Influenza
COVID-19
Others

Nasal Vaccines Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Nasal Vaccines Market.

Available Customizations:

Global Nasal Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nasal Vaccines Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Vaccine Type ( Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, and Conjugate Vaccines, Others)
- 5.2.2. By Application (Influenza, COVID-19, Others (such as Cholera, Typhoid, etc.))
- 5.2.3. By Region
- 5.2.4. By Company (Shares of Top 5 Market Players)
5.3. Market Map
- 5.3.1. By Vaccine Type
- 5.3.2. By Application
- 5.3.3. By Region

6. North America Nasal Vaccines Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Vaccine Type
- 6.2.2. By Application
- 6.2.3. By Country
  - 6.2.3.1. United States Nasal Vaccines Market Outlook
    - 6.2.3.1.1. Market Size & Forecast
    - 6.2.3.1.1.1. By Value
    - 6.2.3.1.2. Market Share & Forecast
    - 6.2.3.1.2.1. By Vaccine Type
    - 6.2.3.1.2.2. By Application
  - 6.2.3.2. Canada Nasal Vaccines Market Outlook
    - 6.2.3.2.1. Market Size & Forecast
    - 6.2.3.2.1.1. By Value
    - 6.2.3.2.2. Market Share & Forecast
    - 6.2.3.2.2.1. By Vaccine Type
    - 6.2.3.2.2.2. By Application
  - 6.2.3.3. Mexico Nasal Vaccines Market Outlook
    - 6.2.3.3.1. Market Size & Forecast
    - 6.2.3.3.1.1. By Value
    - 6.2.3.3.2. Market Share & Forecast
    - 6.2.3.3.2.1. By Vaccine Type
    - 6.2.3.3.2.2. By Application

7. Europe Nasal Vaccines Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Vaccine Type
- 7.2.2. By Application
- 7.2.3. By End User
- 7.2.4. By Country
  - 7.2.4.1. France Nasal Vaccines Market Outlook
    - 7.2.4.1.1. Market Size & Forecast
    - 7.2.4.1.1.1. By Value
    - 7.2.4.1.2. Market Share & Forecast
    - 7.2.4.1.2.1. By Vaccine Type
    - 7.2.4.1.2.2. By Application
  - 7.2.4.2. Germany Nasal Vaccines Market Outlook
    - 7.2.4.2.1. Market Size & Forecast
    - 7.2.4.2.1.1. By Value
    - 7.2.4.2.2. Market Share & Forecast
    - 7.2.4.2.2.1. By Vaccine Type
    - 7.2.4.2.2.2. By Application
  - 7.2.4.3. United Kingdom Nasal Vaccines Market Outlook
    - 7.2.4.3.1. Market Size & Forecast
    - 7.2.4.3.1.1. By Value
    - 7.2.4.3.2. Market Share & Forecast
    - 7.2.4.3.2.1. By Vaccine Type
    - 7.2.4.3.2.2. By Application
  - 7.2.4.4. Italy Nasal Vaccines Market Outlook
    - 7.2.4.4.1. Market Size & Forecast
    - 7.2.4.4.1.1. By Value
    - 7.2.4.4.2. Market Share & Forecast
    - 7.2.4.4.2.1. By Vaccine Type
    - 7.2.4.4.2.2. By Application
  - 7.2.4.5. Spain Nasal Vaccines Market Outlook
    - 7.2.4.5.1. Market Size & Forecast
    - 7.2.4.5.1.1. By Value
    - 7.2.4.5.2. Market Share & Forecast
    - 7.2.4.5.2.1. By Vaccine Type
    - 7.2.4.5.2.2. By Application

8. Asia Pacific Nasal Vaccines Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Vaccine Type
- 8.2.2. By Application
- 8.2.3. By Country
  - 8.2.3.1. China Nasal Vaccines Market Outlook
    - 8.2.3.1.1. Market Size & Forecast
    - 8.2.3.1.1.1. By Value
    - 8.2.3.1.2. Market Share & Forecast
    - 8.2.3.1.2.1. By Vaccine Type
    - 8.2.3.1.2.2. By Application
  - 8.2.3.2. India Nasal Vaccines Market Outlook
    - 8.2.3.2.1. Market Size & Forecast
    - 8.2.3.2.1.1. By Value
    - 8.2.3.2.2. Market Share & Forecast
    - 8.2.3.2.2.1. By Vaccine Type
    - 8.2.3.2.2.2. By Application
  - 8.2.3.3. South Korea Nasal Vaccines Market Outlook
    - 8.2.3.3.1. Market Size & Forecast
    - 8.2.3.3.1.1. By Value
    - 8.2.3.3.2. Market Share & Forecast
    - 8.2.3.3.2.1. By Vaccine Type
    - 8.2.3.3.2.2. By Application
  - 8.2.3.4. Japan Nasal Vaccines Market Outlook
    - 8.2.3.4.1. Market Size & Forecast
    - 8.2.3.4.1.1. By Value
    - 8.2.3.4.2. Market Share & Forecast
    - 8.2.3.4.2.1. By Vaccine Type
    - 8.2.3.4.2.2. By Application
  - 8.2.3.5. Australia Nasal Vaccines Market Outlook
    - 8.2.3.5.1. Market Size & Forecast
    - 8.2.3.5.1.1. By Value
    - 8.2.3.5.2. Market Share & Forecast
    - 8.2.3.5.2.1. By Vaccine Type
    - 8.2.3.5.2.2. By Application

9. South America Nasal Vaccines Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Vaccine Type
- 9.2.2. By Application
- 9.2.3. By Country
  - 9.2.3.1. Brazil Nasal Vaccines Market Outlook
    - 9.2.3.1.1. Market Size & Forecast
    - 9.2.3.1.1.1. By Value
    - 9.2.3.1.2. Market Share & Forecast
    - 9.2.3.1.2.1. By Vaccine Type
    - 9.2.3.1.2.2. By Application
  - 9.2.3.2. Argentina Nasal Vaccines Market Outlook
    - 9.2.3.2.1. Market Size & Forecast
    - 9.2.3.2.1.1. By Value
    - 9.2.3.2.2. Market Share & Forecast
    - 9.2.3.2.2.1. By Vaccine Type
    - 9.2.3.2.2.2. By Application
    - 9.2.3.2.2.3. By End User
  - 9.2.3.3. Colombia Nasal Vaccines Market Outlook
    - 9.2.3.3.1. Market Size & Forecast
    - 9.2.3.3.1.1. By Value
    - 9.2.3.3.2. Market Share & Forecast
    - 9.2.3.3.2.1. By Vaccine Type
    - 9.2.3.3.2.2. By Application

10. Middle East & Africa Nasal Vaccines Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Vaccine Type
- 10.2.2. By Application
- 10.2.3. By Country
  - 10.2.3.1. South Africa Nasal Vaccines Market Outlook
    - 10.2.3.1.1. Market Size & Forecast
    - 10.2.3.1.1.1. By Value
    - 10.2.3.1.2. Market Share & Forecast
    - 10.2.3.1.2.1. By Vaccine Type
    - 10.2.3.1.2.2. By Application
  - 10.2.3.2. Saudi Arabia Nasal Vaccines Market Outlook
    - 10.2.3.2.1. Market Size & Forecast
    - 10.2.3.2.1.1. By Value
    - 10.2.3.2.2. Market Share & Forecast
    - 10.2.3.2.2.1. By Vaccine Type
    - 10.2.3.2.2.2. By Application
  - 10.2.3.3. UAE Nasal Vaccines Market Outlook
    - 10.2.3.3.1. Market Size & Forecast
    - 10.2.3.3.1.1. By Value
    - 10.2.3.3.2. Market Share & Forecast
    - 10.2.3.3.2.1. By Vaccine Type
    - 10.2.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Technology Launches

13. Competitive Landscape

13.1. BiondVax Pharmaceuticals Ltd.
- 13.1.1. Business Overview
- 13.1.2. Application Offerings
- 13.1.3. Recent Developments
- 13.1.4. Key Personnel
- 13.1.5. SWOT Analysis
13.2. Vaxart, Inc.
13.3. FluGen Inc.
13.4. Altimmune, Inc.
13.5. Sinovac Biotech Ltd.
13.6. Sanofi Pasteur SA
13.7. Pfizer Inc.
13.8. GlaxoSmithKline plc
13.9. Johnson & Johnson
13.10. Ennaid Therapeutics, LLC